Best Forestry Companies For 2014

Energy is one of the most critical inputs to the global economy; it heats homes, powers factories and, perhaps most importantly, fuels our cars, trucks and planes. Without energy, no value is added at any link in the economic chain. As a result, the economy as a whole ��and inflation ��is critically sensitive to virtually any shift in global energy prices and oil is energy. That is why rising oil prices tend to play such a causative role in rising inflation.

Interestingly, though, while average gasoline prices have taken a sharp rise since late October, up from an average of $3.19 to the current national average of $3.66, oil prices have been remarkably stable. Despite spikes related to the Russian invasion of Ukraine�� Crimea region and other potential supply disruptions, as you can see from the chart below, the price of oil has been quite stable relative to historical experience.

Top High Dividend Companies To Own For 2015: CRB Futures Index(CR)

Crane Co. manufactures and sells engineered industrial products in the United States and internationally. The company operates in five segments: Aerospace & Electronics, Engineered Materials, Merchandising Systems, Fluid Handling, and Controls. The Aerospace & Electronics segment offers pressure, fuel flow, and position sensors and subsystems; brake control systems; coolant, lube and fuel pumps; and seat actuation products. This segment also provides power supplies and custom microelectronics for aerospace, defense, medical, and other applications; and electrical power components, power management products, electronic radio frequency, and microwave frequency components and subsystems for the defense, space, and military communications markets. The Engineered Materials segment manufactures fiberglass-reinforced plastic panels for the truck trailer and recreational vehicle markets, industrial markets, and the commercial construction industry. The Merchandising Systems segmen t offers vending solutions, such as food, snack, and beverage vending machines; and vending machine software and online solutions, as well as payment solutions, including coin accepters and dispensers, coin hoppers, coin recyclers, bill validators, and bill recyclers. The Fluid Handling segment manufactures and sells various industrial and commercial valves and actuators; provides valve testing, parts, and services; manufactures and sells pumps and water purification solutions; distributes pipe, pipe fittings, couplings, and connectors; and designs, manufactures, and sells corrosion-resistant plastic-lined pipes and fittings. The Controls segment produces ride-leveling, air-suspension control valves for heavy trucks and trailers; pressure, temperature, and level sensors; ultra-rugged computers, measurement and control systems, and intelligent data acquisition products; and water treatment equipment. Crane Co. was founded in 1855 and is based in Stamford, Connecticut.

Advisors' Opinion:

• [By Chuck Carnevale]

  Next, I run graphs on liquidity ratios and additional data on various valuation ratios to include price to book value (pb), price to cash flow (pcfl), price to free cash flow (pfcfl) and others that can be seen as options on the navigation bar to the left of the sample graph which only plots the current ratio (cr), a quick ratio (qr) and for those diehards concerned with volatility [size=11.0pt;line-height:115%; font-family:"Calibri","sans-serif";mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">��/p>

• [By CRWE]

  Crane Co. (NYSE:CR) reported that Andrew L. Krawitt, Vice President, Treasurer and Principal Financial Officer, will be speaking at the 2012 Citi Global Industrials Conference in Boston on Wednesday, September 19, 2012 from 2:00 PM to 2:40 PM.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Crane (NYSE: CR  ) , whose recent revenue and earnings are plotted below.

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Crane (NYSE: CR  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Crane doing by this quick checkup? At first glance, OK, it seems. Trailing-12-month revenue increased 0.6%, and inventory decreased 2.4%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue dropped 2.8%, and inventory contracted 2.4%. Over the sequential quarterly period, the trend looks OK but not great. Revenue dropped 0.4%, and inventory grew 2.0%.

Best Forestry Companies For 2014: Generac Holdlings Inc. (GNRC)

Generac Holdings Inc. designs, manufactures, and markets a range of generators and other engine powered products for the residential, light commercial, industrial, and construction markets in the United States and Canada. It offers generators and other products fueled by natural gas, liquid propane, gasoline, diesel, and Bi-Fuel under the Generac and Magnum brands. The company�s product line includes residential power products, commercial and industrial power products, and other products. Its residential power products comprise automatic residential standby generators that range in output from 6kW to 60kW; air-cooled residential standby generators, which range in outputs from 6kW to 20kW; and liquid-cooled generators that range in outputs from 20kW to 60kW. The residential power product line also includes portable generators consisting of GP series ranging from 1,850W to 17,500W for homeowners; the XG series ranging from 4,000W to 10,000W for the premium homeowner market; the XP series ranging from 4,000W to 8,000W for the professional contractor market; and the iX series ranging from 800W to 2,000W for the recreational market. The company�s industrial and commercial power products comprise light-commercial standby generators ranging from 22kW to 150kW for grocery stores, convenience stores, restaurants, gas stations, pharmacies, retail banks, and healthcare facilities; single-engine industrial generators, which range in output from 10kW to 600kW; and generator systems ranging from 20kW air-cooled generators to 3mW modular power system for the telecommunications market, as well as aftermarket service parts and RV generators. The company sells its generators through independent residential and industrial dealers, wholesalers, national accounts, private label arrangements, retailers, catalogs, e-commerce merchants, equipment rental companies and dealers, and construction companies. Generac Holdings Inc. was founded in 1959 and is headquartere d in Waukesha, Wisconsin.

Advisors' Opinion:

• [By Rich Duprey]

  Generator maker Generac (NYSE: GNRC  ) announced this morning it had completed the refinancing of its senior secured�term loan credit facility and, as it previously promised, will use part of the proceeds to pay investors a special dividend of $5.00 per share,�payable on June 21�to stockholders of record on June 12.�

• [By Eric Volkman]

  Generac (NYSE: GNRC  ) has reached abroad for its latest asset buy. The company announced Thursday that it inked an agreement to acquire Tower Light, an Italy-based company that develops and sells mobile light towers.

• [By Roberto Pedone]

  One diversified machinery player that insiders are snapping up a decent amount of stock in here is Generac (GNRC), which designs, manufactures, and markets power generation equipment and other engine powered products for the residential, light commercial, industrial, and construction markets in the U.S., Canada, and internationally. Insiders are buying this stock into weakness, since shares have dropped notably by 22% so far in 2014.

  Generac has a market cap of $3 billion and an enterprise value of $3.8 billion. This stock trades at a fair valuation, with a trailing price-to-earnings of 17.6 and a forward price-to-earnings of 12.7. Its estimated growth rate for this year is -27%, and for next year it's pegged at 8.9%. This is not a cash-rich company, since the total cash position on its balance sheet is $173.16 million and its total debt is $1.11 billion.

  A director just bought 25,000 shares, or about $1.05 million worth of stock, at $42.17 per share.

  From a technical perspective, GNRC is currently trending above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently formed a triple bottom chart pattern at $39.08, $38.75 and $38.64 a share. Following that bottom, shares of GNRC have started to rebound sharply higher as the stock has pushed back above its 50-day moving average of $42.41 a share. That move has now pushed shares of GNRC within range of triggering a near-term breakout trade.

  If you're bullish on GNRC, then I would look for long-biased trades as long as this stock is trending above its 50-day at $42.41 a share or above more near-term support at $40 a share and then once it breaks out above some near-term overhead resistance levels at $45 to $45.72 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.17 million shares. If that breakout kicks off soon, then GNRC wi

Best Forestry Companies For 2014: Soul And Vibe Interactive Inc (SOUL)

Soul and Vibe Interactive, Inc., incorporated on 5, 2011, is a video and computer games company. The Company develops, publishes and digitally distributes interactive entertainment for video game consoles, mobile devices, and personal computers. It focuses on the development of its products for a variety of hardware platforms: video game consoles (for example: Xbox 360 and PlayStation 3), mobile (for example: Apple iOS and Android devices, and Windows Phones), and personal computers (for example: PC and Mac). The Company has five games, which consists of The Wheaties Challenge, Bugaboo, Grimwhiskers, a virtual-pet game that may bear a licensed-brand, and The Dragon Wars.

The Wheaties Challenge is an adrenaline-charged arcade sports compilation for console, mobile, and personal computer (PC)/Mac. The game promotes family health and wellness, is sponsored by General Mills, and features Wheaties as its signature brand. Bugaboo is an action-puzzle game for consoles, mobile devices and PCs. The core play mechanic is Shadow Weaving. Grimwhiskers is a side scrolling action game for consoles, mobile devices and PCs.

The Company competes with Zynga, Electronic Arts, Activision, Playdom, Ubisoft and Majesco.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Soul and Vibe Interactive Inc (OTCBB: SOUL), Globalstar, Inc (OTCMKTS: GSAT) and Poly Shield Technologies Inc (OTCBB: SHPR) have been getting some attention lately in various investment newsletters or investor alerts with at least two of these stocks being the subject of some sort of paid stock promotional or investor relations type of activities. With that in mind, just how hot are these three small cap stocks for investors or traders? Here is a quick reality check:

• [By Peter Graham]

  Small cap entertainment or gaming stocks Soul and Vibe Interactive Inc (OTCBB: SOUL), Elray Resources Inc (OTCMKTS: ELRA) and Players Network (OTCMKTS: PNTV) focus on entertaining consumers. However, its important to remember that consumers can be very fickle when it comes to entertainment or games. So should you be entertaining any of these small caps? Here is a closer look and a reality check:

Best Forestry Companies For 2014: Asante Gold Corp (ASE)

Asante Gold Corporation is a mineral exploration company involved in the acquisition and assessment of mineral properties in the Republic of Ghana. The Company is a gold royalty, exploration and development company. The Company is focused in Ghana, West Africa where it is exploring the Fahiakoba concession, a 22.07 square kilometers prospecting license located on strike with and between Perseus Mining's 4.32 million ounce Edikan Mine and AngloGold Ashanti's 60 million ounce Obuasi mine. It has a 100% interest in the Fahiakoba concession. ASG Mining Ltd. is the Company�� 100% owned Ghana subsidiary. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Greece�� ASE Index (ASE) retreated 4 percent today, pulled down by shares of lenders. National Bank of Greece SA tumbled 27 percent to 1.15 euros after announcing details of a share sale. Piraeus Bank SA slid 21 percent to 36 euro cents.

Best Forestry Companies For 2014: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By David Zeiler]

  3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.